Greg Verdine, LifeMine Therapeutics CEO
Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24
SAN FRANCISCO — LifeMine Therapeutics, a biotech informed by the long history of fungi, expects to enter the clinic early next year with a T …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
